Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts

Sagimet Biosciences reported a Q3 GAAP EPS loss of -$0.40, missing estimates, but maintains strong momentum with ...

Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity

Zymeworks surges on positive Phase 3 Ziihera data in HER2-positive cancer. Discover key catalysts and what’s next for ZYME stock.
The News Minute

London firm CEO says almost $500 mn Alpha funds went back to Byju Raveendran, he denies it

Follow TNM's WhatsApp channel for news updates and story links.Documents filed in the Delaware Bankruptcy Court in the US on ...